ArticleBioMed research international2021
PLOD2 Is a Potent Prognostic Marker and Associates with Immune Infiltration in Cervical Cancer.
Article in BioMed research international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 16 citations in OpenAlex.
- CCL5 and GLUT1 define leader cells in collective invasion of colorectal cancer.The Journal of pathology · 2026Article
- Recent advancement in inflammatory biomarkers for cervical cancer diagnosis and therapy.Frontiers in oncology · 2026Review
- PLOD2 exacerbates cervical squamous cell carcinoma by suppressing p53 by binding to YAP1.Molecular medicine reports · 2025Article
- Crosstalk of non-apoptotic RCD panel in hepatocellular carcinoma reveals the prognostic and therapeutic optimization.iScience · 2024Article
- PLOD2, a key factor for MRL MSC metabolism and chondroprotective properties.Stem cell research & therapy · 2024Article
- Identification of Potential Genes and Critical Pathways in Postoperative Recurrence of Crohn's Disease by Machine Learning And WGCNA Network Analysis.Current genomics · 2023Article
- PLOD2 promotes colorectal cancer progression by stabilizing USP15 to activate the AKT/mTOR signaling pathway.Cancer science · 2023Article
- Prognostic model based on telomere-related genes predicts the risk of oral squamous cell carcinoma.BMC oral health · 2023Article
- Comprehensive Analysis of the Expression, Prognosis, and Biological Significance of PLOD Family in Bladder Cancer.International journal of general medicine · 2023Article
- PLOD2 Is a Prognostic Marker in Glioblastoma That Modulates the Immune Microenvironment and Tumor Progression.International journal of molecular sciences · 2022Article
- PLOD Family: A Novel Biomarker for Prognosis and Personalized Treatment in Soft Tissue Sarcoma.Genes · 2022Article
- Corrigendum to "PLOD2 Is a Potent Prognostic Marker and Associates with Immune Infiltration in Cervical Cancer".BioMed research international · 2021Article
Corrections and comments
- Erratum issued
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPLOD2 is overexpressed in diverse tumors and plays a vital role in tumorigenesis. However, the prognostic value of PLOD2 in cervical cancer (CESC) remains unclear.
methodsPLOD2 expression and CESC patients' survival data were collected from the Oncomine, GEPIA, UALCAN, and Kaplan-Meier Plotter databases; immunohistochemistry (IHC) was used to validate the expression of PLOD2 in CESC; Gene Set Enrichment Analysis was performed using the STRING and DAVID databases; and the correlations between PLOD2 and cancer immune infiltrates were investigated using the TIMER and TISIDB databases.
resultsWe found that the expression level of PLOD2 was increased in various cancers, and meta-analysis in the Oncomine database revealed that PLOD2 was significantly upregulated in CESC compared to that in normal tissues (
conclusionPLOD2 is positively associated with poor prognosis and might be considered a novel diagnostic and prognostic marker for CESC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.